Frontline Amivantamab Plus Lazertinib Significantly Reduces Mortality in EGFR-Mutant Advanced NSCLC
Amivantamab plus lazertinib provides long-term survival benefit over osimertinib in EGFR-mutated advanced non–small cell lung cancer.
Related Articles
A Career in Clinical Development in Industry: Choose Your Own Adventure
Satya (Nanu) Das, MD, MSCI, pens this piece on what a career in drug development in the biopharmaceutical field may look like.
Blinatumomab Consolidation Prevents B-ALL Relapses and CAR T-Cell Therapy Consolidation May, Too
Gregory Roloff, MD, details data on consolidation therapy with blinatumomab or CAR T-cell therapy for B-ALL, and the role of these agents in this setting.
Post Hoc Analysis of Pooled PERSEUS and GRIFFIN Data Support D-VRd in Transplant-Eligible Myeloma
D-VRd provides PFS benefit and deeper responses vs VRd in transplant-eligible myeloma, according to a post hoc analysis of pooled PERSEUS and GRIFFIN data.
Acimtamig Plus AlloNK Elicits Responses in Heavily Pretreated R/R Hodgkin Lymphoma
Acimtamig plus AlloNK was associated with high objective response rates in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma.
First results of nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability high/ mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW
Dr. Heinz-Josef Lenz presents first results from the CheckMate 8HW trial, demonstrating that nivolumab plus ipilimumab significantly improves progression-free survival and overall response rates compared…
Apraglutide/Ruxolitinib Provides Efficacy Benefit vs Ruxolitinib Alone in Refractory GI aGVHD
A comparative analysis showed that apraglutide plus ruxolitinib improved response rates vs ruxolitinib monotherapy in steroid-refractory GI aGVHD.
Tislelizumab Plus Chemo Expands First-Line ESCC Treatment Paradigm
Nataliya Uboha, MD, PhD, discusses the benefits of expanding the first-line ESCC treatment paradigm with tislelizumab plus chemotherapy.
TTFields/Paclitaxel Fails to Boost OS in Platinum-Resistant Ovarian Cancer But Shows Potential in Key Subgroup
The addition of tumor treating fields to paclitaxel did not lead to a statistically significant overall survival improvement in platinum-resistant ovarian cancer.
Osimertinib After Definitive Chemoradiation Is New SOC for Unresectable Stage III EGFR+ NSCLC
Longer-term outcomes from LAURA further support the benefit of osimertinib over placebo for patients with unresectable stage III EGFR-mutated NSCLC.
Orca-T Is Associated With Retrospective OS Improvement vs Post-Transplant Cyclophosphamide in Advanced Hematologic Malignancies
Orca-T was associated with a retrospective survival improvement vs post-transplant cyclophosphamide in advanced hematologic malignancies.